A Phase III study of FP187 for the treatment of relapsing remitting multiple sclerosis (RRMS) in patients.

Trial Profile

A Phase III study of FP187 for the treatment of relapsing remitting multiple sclerosis (RRMS) in patients.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Interferon beta
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2016 According to a Forward Pharma media release, the company anticipates to start this clinical study in the first half of 2017.
    • 08 Sep 2015 According to Forward Pharma media release, company is planning to initiate this trial in the first half of 2016.
    • 22 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top